BEXSERO Homepage Header

Learn about Bexsero


The persons depicted are models used for illustrative purposes only.

BEXSERO Homepage Header

The persons depicted are models used for illustrative purposes only.


Doctor Discussion

Discussing the COVID-19 vaccination?

Don’t miss the opportunity to mention meningitis B (MenB).


BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

Warning Icon

Don't disregard the threat of MenB

Although meningococcal disease is uncommon, it can progress quickly. In fact, it can lead to death.3

Get the Facts

Stopwatch Icon

Complete their series—fast

Only BEXSERO offers patients the fastest MenB series completion, with 2 doses in as fast as 1 month.1,2

See the Difference

Antigenic Components

Explore the 4 antigens

BEXSERO is the only MenB vaccine that combines 4 different antigenic components.1,2

Learn More

Data Icon

Discover the data

BEXSERO demonstrated serum bactericidal activity against 3 strains selected to measure responses to 3 respective vaccine antigens prevalent among strains in the US.1,*

*Immune response data were recorded for antigens fHbp, NadA, and PorA P1.4. A suitable strain for assessing bactericidal activity of NHBA-specific antibodies was not available.1

See the Results

Webinar Icon

Register for a webinar

Attend a webinar to learn more about meningococcal disease, serogroup B, and vaccination. Sign up today to reserve your spot.

Register Now

Shopping Cart Icon

Place an order today

Stock up on BEXSERO with GSKDirect.

Order Now

Newspaper Icon

Get the latest product updates

Register now for your free account.

Sign up Now

Watch a real MenB survivor story

Vaccination may not protect all recipients.


fHbp=factor H binding protein; NadA=Neisserial adhesin A; NHBA=Neisserial Heparin Binding Antigen; PorA=Porin A P1.4 present in Outer Membrane Vesicles (OMV).